BULLETIN. Slovak Republic Ministry of Health
|
|
|
- Miles Holt
- 8 years ago
- Views:
Transcription
1 BULLETIN Slovak Republic Ministry of Health Part November 13, 2009 No. 57 CONTENTS: 52. Slovak Republic Ministry of Health Guidelines for the Diagnosis of Glucocorticoidinduced Osteoporosis
2 52. Slovak Republic Ministry of Health Guidelines for the Diagnosis of Glucocorticoidinduced Osteoporosis Date: September 28, 2009 Number: 16874/2009-OZS The Slovak Republic Ministry of Health under 45, Paragraph 1, Subparagraph b), of Act No. 576/2004 on healthcare and related services, and upon the amendment and completion of certain acts, as amended, issues this guideline: Article I Subject This guideline provides a summary of the recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Article II Glucocorticoid-induced Osteoporosis 1. Bone mineral density (BMD) begins to decline rapidly within the first 3 months of glucocorticoid use in more than half of patients resulting in glucocorticoid-induced osteoporosis. It is essential to initiate therapy promptly in these patients. Treatment is more agressive than in postmenopausal osteoporosis. 2. Glucocorticoid-induced bone loss is related to: a) Glucocorticoid dose b) Treatment duration 3. Glucocorticoid dose risk is considered: a) Prednisone cummulative dose of 2.7 grams/year b) Prednisone dose per day of 7.5 milligrams or more c) Doses stated in Paragraph 1 and 2 of this Article taken for more than 3 months Article III Healthcare Facilities and Healthcare Professionals For the purpose of this guideline: a) Healthcare facility 1 : 1. Specialised medical clinic/office Internal Medicine, Rheumatology or Orthopaedic surgery 2. Inpatient healthcare facility departments of Internal Medicine, Orthopaedic surgery, and Rheumatology 3. Centralized medical services clinical biochemistry and hematology laboratories 1 7 Act No. 576/2004 Body of Laws on healthcare, healthcare professionals, health care professional association, and upon amendment and completion of certain acts, as amended
3 b) Authorized medical person physician specialised in at least in one of the following specialisations: 1. Endocrinology 2. Rheumatology 3. Orthopaedic surgery Article IV Methods for Assessing Skeletal Health Patients receiving long-term glucocorticoid therapy should undergo the following investigations: a) Whole-body densitometry for patients receiving the following doses of glucocorticoids: 1. Prednisone dose per day greater than 7.5 mg for more than 3 month 2. Cummulative dose of 2.7 grams per year b) Laboratory investigations including the following parameters: 1. aa) Calcium, phosphorous, alkaline phosphatase, serum creatinine bb) 24-hour urine collection for calcium and phosphorous excretion (or urine excretory fractions) 2. Serum and urine bone markers: aa) Bone-resorption markers: Total urinary deoxypyridinoline (DPD), Urinary collagen type I cross-linked C- telopeptide (CTx), Urinary collagen type I cross-linked N-telopeptide (NTx), Serum carboxy-terminal telopeptide of type I collagen (ICTP) bb) Bone-formation markers: Serum bone-specific alkaline phosphatase (BSAP), Serum osteocalcin (OC), Serum procollagen I carboxy-terminal propeptide (PICP), Serum parathomone, 25- hydroxy vitamin D 3. The following markers may be used to monitor treatment effectiveness: aa) One marker of bone resorption bb) Combination of one marker of bone resorption and one marker of bone formation Article V Glucocorticoid-induced Osteoporosis Treatment Algorithm The treatment algorithm applies to patients meeting the criteria listed under Article IV, Section (a), Paragraph 1 and 2 of this guideline: 1. The following universal preventive measures should be followed pursuant to Article VII of glucocorticoid-induced osteoporosis guidelines 2. a) Bone mineral density measurement: If the T-score (i.e. the number of standard deviations above or below the mean value for the healthy young adult reference data) in area of the:
4 I. Lumbar spine and femur is up to 2.0 SD (the standard deviation), repeat measurement after one year of glucocorticoid treatment II. Lumbar spine or femur is 2.0 SD or more, initiate treatment with bisphosphonates III. Femur (femoral neck or total femur) or area of spine is 2.9 SD or more, initiate treatment with teriparatide b) If there is evidence of osteoporotic fracture (vertebra, proximal femur, forearm), initiate treatment with teriparatide Article VI Glucocorticoid-induced Osteoporosis Treatment Algorithm in Males Younger than Age 50 years and Premenopausal Females The treatment algorithm for males younger than age 50 years and premenopausal females is the same as defined in Article V, but in place of T score, the Z score (i.e. the number of standard deviations below the mean for an age-matched population) should be evaluated. Article VII Precautionary Measures It is recommended to follow precautionary measures in patients receiving long-term glucocorticoid therapy: a) Administer the lowest dose of glucocorticoids and minimize the duration of administration b) Exclude risk factors (listed in Appendix) c) Maintain an active lifestyle with adequate sun exposure d) Maintain body mass index above 19 kg/m 2 e) Maintain calcium intake at 1,000-1,500 mg/day f) Maintain Vitamin D intake at 800 IU/day Article VIII Effective The guidelines for glucocorticoid-induced osteoporosis are effective as of November 15, Richard Rasi Minister of Health
5 Appendix to Guidelines No.16874/2009-OZS Osteoporotic Risk Factors in Patients with Glucocorticoid-induced Osteoporosis Factors that increase a person's risk of osteoporosis include: a) History of maternal femoral neck fracture b) History of vertebral, proximal femoral, or forearm fracture following low impact trauma c) Body mass index less than 19 kg/m 2 d) Diseases causing or contributing to osteoporosis: anorexia nervosa, malabsorption, primary hyperparathyroidism, diffuse connective tissue diseases, rheumatoid arthritis, chronic diseases causing intestinal inflammation, post-transplantation syndrome, chronic renal insufficiency, hyperthyroidism, prolonged immobilization, Cushing syndrome, chronic hepatopathy, myeloproliferative disorders, genetic and other metabolic bone disorders e) Height loss of more than 3 cm f) Chronic drug use (anticoagulants, anti-epileptics, thyroid hormones, cytostatics) g) Age: females older than age 65 years and males older than 70 years
Clinical Practice Guideline for Osteoporosis Screening and Treatment
Clinical Practice Guideline for Osteoporosis Screening and Treatment Osteoporosis is a condition of decreased bone mass, leading to bone fragility and an increased susceptibility to fractures. While osteoporosis
Bone Markers in Osteoporosis: Prediction of Fractures & Treatment Monitoring
Bone Markers in Osteoporosis: Prediction of Fractures & Treatment Monitoring Richard Eastell, MD FRCP FRCPath FMedSci, Professor of Bone Metabolism, University of Sheffield, Sheffield, UK Usefulness of
Bone Basics National Osteoporosis Foundation 2013
When you have osteoporosis, your bones become weak and are more likely to break (fracture). You can have osteoporosis without any symptoms. Because it can be prevented and treated, an early diagnosis is
PROTOCOL FOR PATIENTS WITH ABNORMAL LAB AND X-RAY VALUES
PROTOCOL FOR PATIENTS WITH ABNORMAL LAB AND X-RAY VALUES Patients newly diagnosed as osteopenic or osteoporotic on a radiology report or patients receiving abnormal lab values on the following lab tests
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE This is an updated guideline It incorporates the latest NICE guidance There are strong recommendations for calcium + vitamin D
Osteoporosis has been identified by the US Surgeon General
New Guidelines for the Prevention and Treatment of Osteoporosis E. Michael Lewiecki, MD, and Nelson B. Watts, MD Abstract: The World Health Organization Fracture Risk Assessment Tool (FRAX ) and the National
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS IN THE TREATMENT OF PRIMARY OSTEOPOROSIS
European Medicines Agency London, 16 November 2006 Doc. Ref. CPMP/EWP/552/95 Rev. 2 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS IN THE TREATMENT
BONE MINERAL DENSITOMETRY REPORTING
CAR TECHNICAL STANDARDS FOR BONE MINERAL DENSITOMETRY REPORTING APPROVED: JANUARY 25, 2013 KERRY SIMINOSKI, MD, FRCPC; MARGARET O'KEEFFE, MD, FRCPC; JACQUES P. BROWN, MD, FRCPC; STEVEN BURRELL, MD, FRCPC;
Recent Topics in Treatment of Osteoporosis
Review Article Recent Topics in Treatment of Osteoporosis JMAJ 49(9 10): 309 314, 2006 Satoshi Soen* 1 Abstract It has come to light that osteoporosis-related fractures are more critical than previously
Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis. Disclosure and Conflicts of Interest Steven T Harris MD 2014-2015
Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis Steven T Harris MD FACP Clinical Professor of Medicine University of California, San Francisco steve.harris@ucsf.edu Disclosure
Clinical Policy Guideline
Clinical Policy Guideline Policy Title: Bone Density Testing Policy No: B0215A.00 Effective Date: 01/01/15 Date Reviewed: 03/25/15 I. DEFINITION/BACKGROUND Bone density testing is used to estimate the
Osteoporosis Assessment Using DXA and Instant Vertebral Assessment. Working Together For A Healthier Community
Osteoporosis Assessment Using DXA and Instant Vertebral Assessment Working Together For A Healthier Community Osteoporosis The Silent Thief The Facts About Osteoporosis 1 in 2 women will develop osteoporosis
Fast Facts on Osteoporosis
Fast Facts on Osteoporosis Definition Prevalence Osteoporosis, or porous bone, is a disease characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility and an
A Treatment Algorithm for Indian Patients of Osteoporosis
Indian Medical Gazette FEBRUARY 2012 67 Symposia Update A Treatment Algorithm for Indian Patients of Osteoporosis Shailendra Mohan Lakhotia, Senior Consultant Orthopedic Surgeon, Kolkata 700 045. Prashant
Osteoporosis. The inside looks like honeycomb, with blood vessels and bone marrow in the spaces between bone.
Osteoporosis The bones in our skeleton are made of a thick outer shell and a strong inner mesh filled with collagen (protein), calcium salts and other minerals. Osteoporosis The inside looks like honeycomb,
Drug treatment pathway for Osteoporosis in Postmenopausal Women
Drug treatment pathway for Osteoporosis in Postmenopausal Women Version 1.0 Ratified by: East Sussex HEMC Date ratified: 26.01.2011 Job title of originator/author Gillian Ells, East Sussex HEMC Pharmacist
Scans and tests and osteoporosis
Scans and tests and osteoporosis What is osteoporosis? Osteoporosis occurs when the struts which make up the mesh-like structure within bones become thin causing them to become fragile and break easily,
NATIONAL OSTEOPOROSIS FOUNDATION OSTEOPOROSIS CLINICAL UPDATES Vitamin D and Bone Health CE APPLICATION FORM
NATIONAL OSTEOPOROSIS FOUNDATION OSTEOPOROSIS CLINICAL UPDATES Vitamin D and Bone Health CE APPLICATION FORM First Name: Last Name: Mailing Address: City: State: Zip/Postal Code: Country: Phone Number:
Cystic fibrosis and bone health
Cystic fibrosis and bone health Factsheet March 2013 Cystic fibrosis and bone health Introduction As we get older our bones become thinner and weaker, and may become more susceptible to fracture. However
Bone Densitometry. What is a Bone Density Scan (DXA)?
Scan for mobile link. Bone Densitometry Bone densitometry, also called dual-energy x-ray absorptiometry or DEXA, uses a very small dose of ionizing radiation to produce pictures of the inside of the body
Biochemical markers of bone turnover and osteoporosis management
21 Biochemical markers of bone turnover and osteoporosis management Marius Kraenzlin Summary Osteoporosis is defined as a systemic disease characterised by low bone mass and microarchitectural deterioration
Osteoporosis/Bone Health in Adults as a National Public Health Priority
Position Statement Osteoporosis/Bone Health in Adults as a National Public Health Priority This Position Statement was developed as an educational tool based on the opinion of the authors. It is not a
Osteoporosis. Dr Gordon MacDonald BSc MB BChir MRCP Consultant Rheumatologist. Rheumatology and Arthritis Seminar Tuesday 5 th February 2013
Osteoporosis Dr Gordon MacDonald BSc MB BChir MRCP Consultant Rheumatologist Rheumatology and Arthritis Seminar Tuesday 5 th February 2013 Plan What is osteoporosis? Consequences of osteoporosis Risk factors
NATIONAL OSTEOPOROSIS FOUNDATION OSTEOPOROSIS CLINICAL UPDATES Bariatric Surgery And Skeletal Health CE APPLICATION FORM
NATIONAL OSTEOPOROSIS FOUNDATION OSTEOPOROSIS CLINICAL UPDATES Bariatric Surgery And Skeletal Health CE APPLICATION FORM First Name: Last Name: Mailing Address: City: State: Zip/Postal Code: Country: Phone
The effect of alcohol withdrawal on bone turnover in women with alcohol dependence
The effect of alcohol withdrawal on bone turnover in women with alcohol dependence By Pallavi Wyawahare A thesis Submitted to Victoria University of Wellington in partial fulfillment of the requirements
CMAJ JAMC. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada
CANADIAN M EDICAL A SSOCIATION J OURNAL J OURNAL DE L ASSOCIATION MÉDICALE CANADIENNE CMAJ JAMC 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada CMAJ 2002;167(10
NATIONAL OSTEOPOROSIS FOUNDATION OSTEOPOROSIS CLINICAL UPDATES Rehabilitation of Patients With Fragility-Related Fractures CE APPLICATION FORM
NATIONAL OSTEOPOROSIS FOUNDATION OSTEOPOROSIS CLINICAL UPDATES Rehabilitation of Patients With Fragility-Related Fractures CE APPLICATION FORM First Name: Last Name: Mailing Address: City: State: Zip/Postal
Medications for Prevention and Treatment of Osteoporosis
1 Medications for Prevention and Treatment of Osteoporosis Osteoporosis is a disease where the strength of bones is less than normal, making them more susceptible to fracture, or breaking, than normal
Corporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testing_serum_vitamin_d_levels 9/2015 2/2016 2/2017 2/2016 Description of Procedure or Service Vitamin D,
The Diagnosis and Workup of Patients for Osteoporosis or Osteopenia (Low Bone Mass)
The Diagnosis and Workup of Patients for Osteoporosis or Osteopenia (Low Bone Mass) 6 Frank Bonura St. Catherine of Siena Medical Center, Smithtown, NY USA 1. Introduction The rate of screening and treatment
What You Need to Know for Better Bone Health
What You Need to Know for Better Bone Health A quick lesson about bones: Why healthy bones matter The healthier your bones The more active you can be Bone health has a major effect on your quality of life
Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada: Background and Technical Report
Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada: Background and Technical Report Authors: Alexandra Papaioannou MD MSc 1, Suzanne Morin MD MSc 2, Angela M. Cheung
Osteoporosis. Am I at Risk?
Osteoporosis Am I at Risk? TABLE OF CONTENTS What is osteoporosis?...1 Who gets osteoporosis?...2 How can I prevent osteoporosis?...3 How do I know if I have osteoporosis?...4 What is a bone mineral density
PRACTICAL DENSITOMETRY
PRACTICAL DENSITOMETRY The Challenge of Osteoporosis Osteoporosis is a silent disease that develops over decades Goal: identify patients with osteoporosis before fractures occur Means: measure bone density
Healthy Aging Lab: Current Research Abstracts
Healthy Aging Lab: Current Research Abstracts Arsenic Exposure and Women s Health Environmental exposure to inorganic arsenic is an indisputable source of increased risk of several human cancers and chronic
DEFINITION OF OSTEOPOROSIS
CHAPTER 27 OSTEOPOROSIS AND OSTEOMALACIA DEFINITION OF OSTEOPOROSIS THE EPIDEMIOLOGY AND CONSEQUENCES OF OSTEOPOROSIS REVIEW OF BONE REMODELING BONE LOSS PATHOGENESIS OF OSTEOPOROSIS DIAGNOSIS OF OSTEOPOROSIS
Treatment of osteoporosis in fragility fractures
Orthogeriatrics Clinical Summary Document Treatment of osteoporosis in fragility fractures Fragility fractures are extremely prevalent in older adults with a staggering cost of treatment. As the population
NOFSA Guideline for the Diagnosis and Management of Osteoporosis
NOFSA Guideline for the Diagnosis and Management of Osteoporosis Stephen Hough, Brynne H Ascott-Evans, Susan L Brown, Bilkish Cassim, Tobie J de Villiers, Stan Lipschitz, John M Pettifor and Ernst WW Sonnendecker
PRODUCT MONOGRAPH FORTEO. [teriparatide (rdna origin) injection]
![PRODUCT MONOGRAPH FORTEO. [teriparatide (rdna origin) injection]](/thumbs/40/20856910.jpg "PRODUCT MONOGRAPH FORTEO. [teriparatide (rdna origin) injection]")
PRODUCT MONOGRAPH Pr FORTEO [teriparatide (rdna origin) injection] Sterile Solution for Subcutaneous Injection 250 mcg/ml in 3 ml prefilled pen 250 mcg/ml in 2.4 ml prefilled pen Bone Formation Agent Eli
American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of
merican ollege of Rheumatology 2 Recommendations for the Prevention and Treatment of G L U O O R T I O I D - I N D U E D O S T E O P O R O S I S L I N I I N S G U I D E The objective of this guide is to
Bone Basics National Osteoporosis Foundation 2013
Certain people are more likely to develop osteoporosis than others. While you have no control over some risk factors for osteoporosis, there are others you can change. By making healthier choices you can
Osteoporosis Clinical guideline for prevention and treatment
Osteoporosis Clinical guideline for prevention and treatment Executive Summary Updated November 2014 National Osteoporosis Guideline Group on behalf of the Bone Research Society, British Geriatrics Society,
RISK EVALUATION AND MITIGATION STRATEGY (REMS)
Page 1 Initial REMS Approval: July 2009 Most Recent Modification: August 2013 NDA 21-318 FORTEO (teriparatide) (rdna origin) Injection RISK EVALUATION AND MITIGATION STRATEGY (REMS) Eli Lilly and Company
Osteoporosis and Arthritis: Two Common but Different Conditions
and : Two Common but Different Conditions National Institutes of Health and Related Bone Diseases ~ National Resource Center 2 AMS Circle Bethesda, MD 20892 3676 Tel: 800 624 BONE or 202 223 0344 Fax:
Osteoporosis Update. Laura E. Ryan, MD
Osteoporosis Update Laura E. Ryan, MD Assistant Director for Special Programs Center for Women s Health Clinical Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
DOI 10.1007/s00198-010-1501-1 POSITION PAPER Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards S. Vasikaran
How To Choose A Biologic Drug
North Carolina Rheumatology Association Position Statements I. Biologic Agents A. Appropriate delivery, handling, storage and administration of biologic agents B. Indications for biologic agents II. III.
MOH/P/PAK/240.12(GU) June 2012. Clinical Guidance on Management. Osteoporosis 2 0 12. Malaysian Osteoporosis Society
MOH/P/PAK/240.12(GU) June 2012 Clinical Guidance on Management of Osteoporosis 2 0 12 Malaysian Osteoporosis Society Academy of Medicine Ministry of Health Malaysia Published by: Malaysian Osteoporosis
16. ARTHRITIS, OSTEOPOROSIS, AND CHRONIC BACK CONDITIONS
16. ARTHRITIS, OSTEOPOROSIS, AND CHRONIC BACK CONDITIONS Goal Reduce the impact of several major musculoskeletal conditions by reducing the occurrence, impairment, functional limitations, and limitation
FRAX Identifying people at high risk of fracture
FRAX Identifying people at high risk of fracture WHO Fracture Risk Assessment Tool, a new clinical tool for informed treatment decisions Authored by Dr. Eugene McCloskey International Osteoporosis Foundation
Osteoarthritis and osteoporosis
Osteoarthritis and osteoporosis What is osteoporosis? Osteoporosis occurs when the struts which make up the mesh-like structure within bones become thin causing them to become fragile and break easily,
Clinician s Guide. to Prevention and Treatment of Osteoporosis. Developed by the National Osteoporosis Foundation
Clinician s Guide to Prevention and Treatment of Osteoporosis Developed by the National Osteoporosis Foundation Clinician s Guide to Prevention and Treatment of Osteoporosis Developed by the National Osteoporosis
Easy-to-Read Information for Patients and Families. U.S. Department of Health and Human Services National Institutes of Health
BONE HEALTH FOR LIFE Easy-to-Read Information for Patients and Families U.S. Department of Health and Human Services National Institutes of Health National Institute of Arthritis and Musculoskeletal and
Secondary Causes of Osteoporosis The female athlete triad secondary osteoporosis Chronic Conditions Chronic digestive tract conditions
Spring 2009 Newsletter # 23 Biannual Newsletter The Creighton University Osteoporosis Research Center Secondary Causes of Osteoporosis (Much of this content has been adapted from materials provided by
Requests. Who requests a DXA scan? DXA. DXA Technology. Adequate Clinical Information
Requests Define a protocol for validation and prioritisation of densitometry requests. Registered medical practitioners In writing Include adequate clinical information Unsuitable requests should be discussed
CPT 76977, 77078, 77079, 77080, 77081, 77083, or HCPCS G0130:
Bone Mass Measurements Coverage Information Noridian Administrative Services (NAS), LLC, is providing coverage information regarding Bone Mass Measurements (BMM) in response to multiple provider inquiries.
Margaret French, Specialist Nurse, Fracture Liaison Service Glasgow Royal Infirmary Rachel Lewis Rheumatology Specialist Physiotherapist, North
Margaret French, Specialist Nurse, Fracture Liaison Service Glasgow Royal Infirmary Rachel Lewis Rheumatology Specialist Physiotherapist, North Bristol NHS Trust Very informal workshop to facilitate discussion
Guidance for the Management of Breast Cancer Treatment-Induced Bone Loss
Guidance for the Management of Breast Cancer Treatment-Induced Bone Loss A consensus position statement from a UK Expert Group Reviewed and supported by the National Osteoporosis Society (NOS), the National
PRODUCT MONOGRAPH. Risedronate Sodium (as the hemi-pentahydrate) Tablets, USP 5 mg, 30 mg, 35 mg, 75 mg and 150 mg
PRODUCT MONOGRAPH Risedronate Sodium (as the hemi-pentahydrate) Tablets, USP 5 mg, 30 mg, 35 mg, 75 mg and 150 mg Risedronate Sodium (as the hemi-pentahydrate) Delayed-Release Tablets 35 mg Warner Chilcott
OSTEOPOROSIS REHABILITATION PROGRAM
OSTEOPOROSIS REHABILITATION PROGRAM Tricia Orme, R.N. BSc(N) Mary Pack Arthritis Program Victoria i Arthritis i Centre Objectives Participants will gain an understanding of what Osteoporosis is and how
Contractor Information. LCD Information. Contractor Name First Coast Service Options, Inc. Document Information LCD ID L32100
Local Coverage Determination (LCD): Bisphosphonates (Intravenous [IV]) and Monoclonal Antibodies in the Treatment of Osteoporosis and Their Other Indications (L32100) Contractor Information Contractor
X-Plain Vertebral Compression Fractures Reference Summary
X-Plain Vertebral Compression Fractures Reference Summary Introduction Back pain caused by a vertebral compression fracture, or VCF, is a common condition that affects thousands of people every year. A
Orthopaedic Issues in Adults with CP: If I Knew Then, What I Know Now
Orthopaedic Issues in Adults with CP: If I Knew Then, What I Know Now Laura L. Tosi, MD Director, Bone Health Program Children s National Medical Center Washington, DC Epidemiology 87-93% of children born
BISPHOSPHONATE RELATED OSTEONECROSIS OF THE JAW (BRONJ) BISPHOSPHONATES AND WHAT HAPPENS TO BONE VINCENT E. DIFABIO, DDS, MS MEMBER OF THE COMMITTEE ON HEALTHCARE AND ADVOCACY FROM THE AMERICAN ASSOCIATION
Resorptive Changes of Maxillary and Mandibular Bone Structures in Removable Denture Wearers
Resorptive Changes of Maxillary and Mandibular Bone Structures in Removable Denture Wearers Dubravka KnezoviÊ-ZlatariÊ Asja»elebiÊ Biserka LaziÊ Department of Prosthodontics School of Dental Medicine University
ANTIESTROGENIC tamoxifen, widely used for treatment
0021-972X/98/$03.00/0 Vol. 83, No. 4 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1998 by The Endocrine Society Comparison of Effects of Tamoxifen and Toremifene on Bone
Osteoporosis Treatment Guide
Osteoporosis Treatment Guide An estimated 10 million Americans have osteoporosis. Another 34 million have low bone mass. If left untreated, osteoporosis can be both debilitating and painful. Fortunately,
Medications to Prevent and Treat Osteoporosis
Medications to Prevent and Treat Osteoporosis National Institutes of Health Osteoporosis and Related Bone Diseases ~ National Resource Center 2 AMS Circle Bethesda, MD 20892-3676 Tel: (800) 624-BONE or
POSITION STATEMENT Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society
Menopause: The Journal of The North American Menopause Society Vol. 13, No. 3, pp. 340-367 DOI: 10.1097/01.gme.0000222475.93345.b3 * 2006 by The North American Menopause Society 5 Text printed on acid-free
The threshold of bone mineral density for vertebral fractures in female patients with primary hyperparathyroidism
European Journal of Endocrinology (2005) 153 373 378 ISSN 0804-4643 CLINICAL STUDY The threshold of bone mineral density for vertebral fractures in female patients with primary hyperparathyroidism Hiroshi
Osteoporosis: The Need for Prevention and Treatment
Karan Baucom, MD a Lara Pizzorno, MA b Joseph Pizzorno, ND b 2014, Karan Baucom, MD Journal Compilation 2014, AARM DOI 10.14200/jrm.2014.3.0102 ABSTRACT Osteoporosis is a preventable, potentially crippling
Steroid-Induced Osteoporosis: First, Do No Harm. Karen E. Hansen, M.D. Assistant Professor of Medicine Rheumatology Section University of WI
Steroid-Induced Osteoporosis: First, Do No Harm Karen E. Hansen, M.D. Assistant Professor of Medicine Rheumatology Section University of WI This CME program is sponsored by an unrestricted educational
Prevention and Treatment of Corticosteroid-Induced Osteoporosis
Yonsei Medical Journal Vol. 46, No. 4, pp. 456-463, 2005 Prevention and Treatment of Corticosteroid-Induced Osteoporosis Jun Iwamoto, 1 Tsuyoshi Takeda, 1 and Yoshihiro Sato 2 1 Department of Sports Medicine,
Southern Derbyshire Shared Care Pathology Guidelines. Vitamin D
Southern Derbyshire Shared Care Pathology Guidelines Vitamin D Purpose of guideline Provide clear advice on when to measure vitamin D and identify patients with insufficiency and deficiency. To provide
Bone Densitometry and the Treatment of Osteoporosis
Reference Section Bone Densitometry and the Treatment of steoporosis a report by Dr Glen Blake and Professor Ignac Fogelman Senior Lecturer, and Professor of Nuclear Medicine, Guy s, King s and St Thomas
NAMS continuing medical education activity
Menopause: The Journal of The North American Menopause Society Vol. 17, No. 1, pp. 23/24 DOI: 10.1097/gme.0b013e3181cdd4a7 * 2010 by The North American Menopause Society 5 Text printed on acid-free paper
Osteoporosis: key concepts. Azeez Farooki, MD Endocrinologist
Osteoporosis: key concepts Azeez Farooki, MD Endocrinologist Outline I) Composition of bone II) Definition & pathophysiology of osteoporosis III) Peak bone mass IV) Secondary osteoporosis V) Vitamin D
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
DOI 10.1007/s00198-012-2074-y POSITION PAPER European guidance for the diagnosis and management of osteoporosis in postmenopausal women J. A. Kanis & E. V. McCloskey & H. Johansson & C. Cooper & R. Rizzoli
Osteoporosis and you. Find out about the implications of osteoporosis and what you can do for your bone health
Osteoporosis and you Find out about the implications of osteoporosis and what you can do for your bone health 2 What is osteoporosis? Osteoporosis, which literally means porous bone, is a disease in which
Back & Neck Pain Survival Guide
Back & Neck Pain Survival Guide www.kleinpeterpt.com Zachary - 225-658-7751 Baton Rouge - 225-768-7676 Kleinpeter Physical Therapy - Spine Care Program Finally! A Proven Assessment & Treatment Program
Prolia 2 shots a year proven to help strengthen bones.
Ask your doctor if Prolia (denosumab) is right for you and visit us at www.prolia.com For women with postmenopausal osteoporosis at high risk for fracture: there s Prolia. Prolia 2 shots a year proven
Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use
0163-769X/05/$20.00/0 Endocrine Reviews 26(5):688 703 Printed in U.S.A. Copyright 2005 by The Endocrine Society doi: 10.1210/er.2004-0006 Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis:
Calcium (serum, plasma, blood)
Calcium (serum, plasma, blood) 1 Name and description of analyte 1.1 Name of analyte Calcium (total in serum, plasma, ionised in blood (see 2.1 (2)). 1.2 Alternative names None 1.3 NMLC code 1.4 Description
Osteoporosis is a common and costly systemic disease
OUTCOMES IN PRACTICE Osteoporosis Disease Management: Best Practices from the Penn State Geisinger Health System Eric D. Newman, MD, Ralph H. Starkey, MD, William T. Ayoub, MD, FACP, FACR, Charles M. Davis
Facts About Aging and Bone Health
Facts About Aging and Bone Health A Guide to Better Understanding and Well Being with the compliments of Division of Health Services Diocese of Camden Exercise as treatment Along with medication, proper
Osteoporosis Medications
Osteoporosis Medications When does a doctor prescribe osteoporosis medications? Healthcare providers look at several pieces of information before prescribing a bone- preserving or bone- building medication.
Go to Table of Contents. The Man s Guide. to Osteoporosis. National Osteoporosis Foundation
Go to Table of Contents The Man s Guide to Osteoporosis National Osteoporosis Foundation Contents Introduction... 2 Chapter 1: Start with bone healthy behaviors... 3 Get the calcium and vitamin D you need
See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 3/2016
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FOSAMAX safely and effectively. See full prescribing information for FOSAMAX. FOSAMAX (alendronate
OSTEOPOROSIS -Medical Management of Men and Women who have (or are at risk of ) Osteoporosis
Basingstoke, Southampton and Winchester District Prescribing Committee OSTEOPOROSIS -Medical Management of Men and Women who have (or are at risk of ) Osteoporosis Frail, increased fall risk + housebound
Prevention of Osteoporosis
www.bpac.org.nz keyword: osteoporosis Prevention of Osteoporosis Key reviewers: Professor Ian Reid, Faculty of Medical and Health Sciences, University of Auckland Dr Rebecca Grainger, Rheumatologist and
Stickler Syndrome and Arthritis
Stickler Syndrome and Arthritis Arthritis Foundation Pacific Region, Nevada Office Presented by: Crystal Schulz, MPH Community Development Manager Arthritis Foundation Improving lives through leadership
Bone Health Among Premenopausal Female Alcoholics: A Pilot Study
Send Orders for Reprints to reprints@benthamscience.ae 14 The Open Bone Journal, 2015, 7, 14-18 Open Access Bone Health Among Premenopausal Female Alcoholics: A Pilot Study M.A. Clynes 1, P. Wyawahare
Osteoporosis is typically considered to be
THE IMPACT OF LONG-TERM ANTIEPILEPTIC DRUG USE ON BONE HEALTH * Alison M. Pack, MD ABSTRACT A growing amount of scientific literature describing long-term follow-up in patients taking antiepileptic drugs
Osteoporosis in elderly: prevention and treatment
Clin Geriatr Med 18 (2002) 529 555 Osteoporosis in elderly: prevention and treatment Manish Srivastava, MD a, Chad Deal, MD b, * a Section of Geriatric Medicine, A91 Cleveland Clinic Foundation, 9500 Euclid
I. INCLUSION AND EXCLUSION CRITERIA
Page 1 of 5 I. INCLUSION AND EXCLUSION CRITERIA INCLUSION CRITERIA Yes No 1. Patient is diagnosed with according to the American College of Rheumatology 1987 revised criteria. 2. All 4 grandparents are
Osteoporosis. CME Objective: To review current evidence for the prevention, diagnosis, and treatment of osteoporosis.
Section Editors Deborah Cotton, MD, MPH Darren Taichman, MD, PhD Sankey Williams, MD Physician Writer E. Michael Lewiecki, MD Osteoporosis Screening and Prevention Diagnosis and Evaluation Treatment Patient
SUMMARY OF THE RISK MANAGEMENT PLAN (by medicinal product)
PART VI SUMMARY OF THE RISK MANAGEMENT PLAN (by medicinal product) Format and content of the summary of the RMP The summary of the RMP part VI contains information based on RMP modules SI, SVIII and RMP
OsteOpOrOsis Guidelines
OsteOpOrOsis Guidelines FOr health professionals [these are not actors] OsteOpOrOsis Guidelines FOr health professionals The Irish Osteoporosis Society wish to acknowledge the support of an unrestricted
Osteoporosis: Nonclinical Evaluation of Drugs Intended for Treatment Guidance for Industry
Osteoporosis: Nonclinical Evaluation of Drugs Intended for Treatment Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions